Skip to content

Plazomicin

ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: ACHN-490, plazomicin sulfate

OfmFDA approvedATC J01GB14

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Plazomicin is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 2018. Recorded indications include Urinary tract infectious disease.

  • Approval status: ofm (first approved 2018 by the FDA).
  • Indications: Urinary tract infectious disease.
  • ATC code: J01GB14 (Other aminoglycosides).
  • Molecular formula: C25H48N6O10; molecular weight 592.69 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Urinary tract infectious disease

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2018-06-25FDA—ACHAOGEN INC

ATC classification

ATC codeTherapeutic hierarchy
J01GB14ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › AMINOGLYCOSIDE ANTIBACTERIALS › Other aminoglycosides

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • FDA label: MT-RNR1 · Actionable PGx

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Plazomicin is on its molecule page.

Molecular formulaC25H48N6O10
Molecular weight592.69 g/mol
CAS number1154757-24-0
InChIKeyIYDYFVUFSPQPPV-PEXOCOHZSA-N
PubChem CID42613186
CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Plazomicin used for?

DrugCentral lists the following indications for Plazomicin: Urinary tract infectious disease.

When was Plazomicin first approved?

Plazomicin was first approved by the FDA in 2018.

What is the chemical formula of Plazomicin?

Plazomicin has the molecular formula C25H48N6O10 and a molecular weight of 592.69 g/mol.

Browse: all drugs starting with P · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval2018-06-25
AgencyFDA
Targets0
Indications1
FormulaC25H48N6O10
DrugCentral ID5287
Interactive profile